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http://www.biomedcentral.com/1471-2369/13/127RESEARCH ARTICLE Open AccessPlatelets of patients with chronic kidney disease
demonstrate deficient platelet reactivity in vitro
Esther R van Bladel1†, Rosa L de Jager2†, Daisy Walter1, Loes Cornelissen1, Carlo A Gaillard2,3, Leonie A Boven2,
Mark Roest1 and Rob Fijnheer1,2*Abstract
Background: In patients with chronic kidney disease studies focusing on platelet function and properties often are
non-conclusive whereas only few studies use functional platelet tests. In this study we evaluated a recently
developed functional flow cytometry based assay for the analysis of platelet function in chronic kidney disease.
Methods: Platelet reactivity was measured using flow cytometric analysis. Platelets in whole blood were triggered
with different concentrations of agonists (TRAP, ADP, CRP). Platelet activation was quantified with staining for
P-selectin, measuring the mean fluorescence intensity. Area under the curve and the concentration of half-maximal
response were determined.
Results: We studied 23 patients with chronic kidney disease (9 patients with cardiorenal failure and 14 patients
with end stage renal disease) and 19 healthy controls. Expression of P-selectin on the platelet surface measured as
mean fluorescence intensity was significantly less in chronic kidney disease patients compared to controls after
maximal stimulation with TRAP (9.7 (7.9-10.8) vs. 11.4 (9.2-12.2), P = 0.032), ADP (1.6 (1.2-2.1) vs. 2.6 (1.9-3.5), P = 0.002)
and CRP (9.2 (8.5-10.8) vs. 11.5 (9.5-12.9), P = 0.004). Also the area under the curve was significantly different. There
was no significant difference in half-maximal response between both groups.
Conclusion: In this study we found that patients with chronic kidney disease show reduced platelet reactivity in
response of ADP, TRAP and CRP compared to controls. These results contribute to our understanding of the
aberrant platelet function observed in patients with chronic kidney disease and emphasize the significance of using
functional whole blood platelet activation assays.
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In chronic kidney disease both bleeding and thrombotic
complications are observed. It has been hypothesized
that this disturbed balance between pro- and anti-
haemostatic factors is involved in the high morbidity
and mortality reported in chronic kidney disease [1-4].
Early stages of chronic kidney disease are typically asso-
ciated with a prothrombotic tendency, whereas in its
more advanced stage patients also suffer from a bleeding
diathesis [5].* Correspondence: r.fijnheer@meandermc.nl
†Equal contributors
1Department of Clinical Chemistry and Hematology, University Medical
Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands
2Department of Internal Medicine and Laboratory Medicine, Meander
Medical Center, Utrechtseweg 160, 3800 BM, Amersfoort, The Netherlands
Full list of author information is available at the end of the article
© 2012 van Bladel et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumBleeding tendency of patients is characterized by haem-
orrhagic symptoms and by prolongation of bleeding time
[6]. The cause of bleeding in this group of patients has
been elaborated in the past and the pathogenesis seems
multifactorial. It is suggested that abnormal platelet func-
tion is a major contributor, since haemorrhage occurs des-
pite a coagulation profile of normal or elevated levels of
coagulation factors and normal platelet counts [4,6]. Plate-
let dysfunction may be the result of decreased dense gran-
ule content, decreased sensitivity to platelet agonists,
abnormal expression of platelet glycoproteins, defective
arachidonate metabolism and depressed prostaglandin
metabolism as well as impaired platelet adhesiveness.
Platelet dysfunction is thought to be caused by the action
of uremic toxins, anemia, increased nitric oxide produc-
tion, von Willebrand factor abnormalities and the use oftral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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drugs and β-lactam antibiotics [4,6-8]. Besides an increased
bleeding risk, a variety of thrombotic complications are
observed in patients with chronic renal failure, including
coronary heart disease, cerebrovascular disease, peripheral
vascular disease and heart failure. Already in mild to mod-
erate chronic kidney disease an increased risk of cardiovas-
cular events and higher mortality have been reported
[1,2,9-12].
The balance between thrombosis and bleeds is dis-
turbed in chronic kidney disease. Functional platelet
tests are needed to obtain more insight into this balance.
However, up to know only a minority of the studies used
functional platelet tests and results are non-conclusive
[6,13]. This is probably due to in vitro artifacts as a re-
sult of the procedure of platelet isolation, influence of
plasma proteins and influence of hematocrit. Therefore
we have set up this study with a recently developed, flow
cytometer based, functional platelet assay in whole
blood, in which these factors are not of influence. With
this assay we assessed platelet reactivity in patients with
end stage renal disease and cardiorenal syndrome. Both
platelet sensitiveness as well as maximal activation of
platelets in response to 3 different platelet stimuli was
measured, providing an explanation for the disturbed
haemostatic balance in patients with renal failure.
Methods
Subjects
Patients were selected from the out-patient clinic of the
Meander Medical Center in Amersfoort for this prospect-
ive, observational study. Two groups of patients with
chronic kidney disease were recruited. The first group
consisted of patients with end stage renal disease receiving
hemodialysis [14]. In patients on hemodialysis, blood sam-
ples were collected before and also immediately after
hemodialysis (pre versus post dialysis). All samples were
collected using citrate tubes and mixed gently. The second
group consisted of patients with cardiorenal syndrome,
defined as coexistence of chronic kidney disease and
chronic heart failure [15]. Chronic kidney disease in this
group was defined as eGFR<70 ml/min without require-
ment of hemodialysis. Chronic heart failure was defined as
NYHA class II or higher, based on symptoms, signs and
objective abnormality on echocardiography [16]. Controls
included subjects recruited from among healthy hospital
staff, healthy subjects attending the hospital for control
follow up and healthy partners of patients. Patients were
excluded from the study based on the following criteria:
clinical signs of infection, malignancy, primary haemo-
static disorders unrelated to uremia, treatment with im-
munosuppressive drugs, use of antiplatelet agents (except
aspirin) such as clopidogrel, dipyridamole or non-steroidal
anti-inflammatory drugs and the inability to provideinformed consent. The protocol was approved by the local
medical ethical committee of Meander Medical Center
Amersfoort and both patients and control volunteers gave
written informed consent to participate in the study.
Blood sampling and processing
In patients on haemodialysis, the samples were collected
before starting the haemodialysis and immediately after
the procedure. The first sample was taken from the affer-
ent line directly after inserting the needle in the fistula.
The second sample was taken directly after dialysis from
the efferent line out of the dialysis machine. In control
subjects peripheral venous blood samples were collected
from the antecubital vein using 21 gauge needles. A total
of 4.5 mL blood was drawn into vacutainer tubes contain-
ing 0.5 mL 3.2% sodium-citrate solution as anticoagulant
and mixed gently. Blood cell count assays were performed
using a haematology analyzer (Sysmex, Etten-Leur, The
Netherlands). Hemoglobin, hematocrit, and platelet count
were noted.
Materials
For our samples we used HEPES-buffered saline (HBS) con-
taining 10 mM HEPES (BDH biochemical, UK), 150 mM
NaCl (Sigma-Aldrich, Zwijndrecht, the Netherlands), 1 mM
MgSO4 (Riedel de Haën, Hannover, Germany) and
5 mM KCl (Riedel de Haën), with a pH of 7.4. Fixation
was done with a fixation buffer containing 0.2% for-
maldehyde (Calbiochem, Merck, Darmstadt, Germany)
in 0.9% NaCL (Sigma-Aldrich). Used fluorochrome-
labeled ligands were anti-CD42b fluorescein isothio-
cyanate (FITC)-labeled mouse antihuman antibody (BD
Pharmingen™, San Diego, California, USA) and anti-
CD62P phycoerythrin (PE)-labeled mouse antihuman
antibody (BD Pharmingen™). Adenosine diphosp-
hate (ADP) (Roche, Almere, the Netherlands) was used
as agonist, as well as thrombin-receptor-associated-
peptide (TRAP) (Bachem, Weil am Rhein, Germany) and
cross-linked collagen related peptide (CRP) was a gener-
ous gift of R. Farndale (Cambridge, United Kingdom).
Platelet reactivity
Assays were performed as described before [17]. In short,
5 μL of whole blood was added to tubes containing 50 μL
of HBS, fluorochrome-labeled ligands and serial dilutions
of agonists. Anti-CD42b FITC-labeled monoclonal anti-
bodies were used as an activation-independent platelet
marker. PE-labeled anti-CD62P was used as an activation-
dependent marker. For each agonist eight different con-
centrations were used, with four times dilution steps
between each sample. Concentrations of TRAP were 0.038
to 625 μmol/L, ADP 0.008 to 125 μmol/L, and CRP 0.2 to
2500 ng/mL. After incubation at room temperature for
20 minutes, platelets were fixed by the addition of 500 μL
Table 1 Baseline characteristics in patients with chronic
kidney disease and controls
Baseline characteristics Controls CKD P-value
N=19 N=23
Age, y (IQR) 62 (48-71) 78 (64-83) 0.043
Male, n (%) 13 (68.4) 15 (65.2) 0.755
Hemoglobin, mmol/L (IQR) 9.4 (9.0-9.9) 7.2 (6.7-7.8) 0.006
Hematocrit, L/L (IQR) 0.44 (0.43-0.47) 0.36 (0.34-0.38) 0.001
Platelet count, 109/L (IQR) 210 (150-240) 187 (160-225) 0.223
Hemodialysis, n (%) NA 14 (60.9) -
Cardiorenal syndrome, n (%) NA 9 (39.1) -
EPO use, n (%) NA 5 (21.7) -
Aspirin use, n (%) 0 11 (47.8) -
CKD chronic kidney disease, IQR inter quartile range, EPO erythropoietin.
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were 3.5 times diluted with the same fluid for flow cyto-
metric analysis. Samples were analyzed by flow cytometry
on a Epics XL-MCL Flow Cytometer (Beckman Coulter,
Miami, Florida, USA) and EXPO 32 MultiCOMP Software
(Beckman Coulter) was used to process the data. The
platelet population was identified by forward and 90° side
scatter properties in combination with a positive CD42b
signal. Isotype control antibodies were used to correct for
aspecific binding. The mean fluorescence intensity (MFI)
of all platelets is expressed in arbitrary units (AU).
Statistical analysis
GraphPad software version 4.0 for Windows (GraphPad
Software, San Diego, California USA) was used to draw
graphs and to calculate EC50. EC50 is defined as the con-
centration of the agonist needed to achieve an effect on
the platelets halfway between the maximum and mini-
mum. Area under the curve (AUC) was calculated in SPSS
by adding up the outcome minus basal activation outcome
of all concentrations points. The data were analyzed by lo-
gistic regression for scaled data. For comparisons of nom-
inal variables a Chi-square cross tabulation with a Fisher’s
Exact test was used. Statistical analyses were undertaken
using SPSS software version 15.0 (SPSS Inc, Chigaco,
Illinois). A P-value of < 0.05 was considered as statistically
significant. Values are given as median with interquartile
range (IQR) if not noted otherwise.
Results
Patient characteristics
Twenty-three patients with chronic kidney disease and
19 healthy controls were included. In the chronic kidney
disease group, we included 9 patients with cardio renal
syndrome and 14 patients with end stage renal failure on
hemodialysis (analyzed before and immediate after dialy-
sis). Clinical and laboratory characteristics are listed in
Table 1. Age was significantly higher in patients (78 years
(64-83)) compared to controls (62 years (48-71)). As
expected hemoglobin and hematocrit level were signifi-
cantly lower in cardio renal syndrome patients compared
to controls. There were no significant differences in
platelet count. The etiology of chronic kidney disease
was divers: hypertension (n = 7), diabetic nephropathy
(n = 4), membranous glomerulopathy (n = 1), rapid pro-
gressive IgA nephropathy (n = 1), chronic pyelonephritis
(n = 1), polycystic nephropathy (n = 1), nephrosclerosis
(n = 1) or unknown cause (n = 7). The etiology of chronic
heart failure was of ischemic origin (n = 5), valvular heart
disease (n = 3) or unknown (n = 1).
Platelet reactivity
Expression of P-selectin on the platelet surface measured
as MFI was significantly lower in chronic kidney diseasepatients compared to controls after maximal stimulation
with TRAP (9.7 (7.9-10.8) vs. 11.4 (9.2-12.2), P = 0.032),
ADP (1.6 (1.2-2.1) vs. 2.6 (1.9-3.5), P = 0.002) and CRP (9.2
(8.5-10.8) vs. 11.5 (9.5-12.9), P = 0.004). (Figure 1 and
Table 2). Maximal P-selectin expression in response to dif-
ferent agonist correlated significantly with each other
(Spearmann’s Rho correlation TRAP and ADP 0.684 with
p< 0.001; TRAP and CRP 0.538 with p< 0.001; ADP and
CRP 0.475 with p=0.001). Table 2 shows that the EC50
was not different between chronic kidney disease patients
and controls.
Chronic kidney disease patients showed significantly
lower platelet reactivity as compared to healthy control sub-
jects for TRAP (AUC : 39.5 (32.9-44.4) vs. 47.1 (41.1-54.2),
P=0.01) and ADP (AUC: 5.8 (3.8-7.3) vs. 8.9 (7.9-12.2),
P=0.002) when measured with AUC (Table 2). Stimulation
with CRP (AUC: 23.4 (18.9-34.79) vs. 30.3 (22.1-41.9),
p= 0.06) does not show a difference in reactivity between
the groups.
Since age was significant lower in the control group
we adjusted for this in a regression analysis. The signifi-
cant difference in MFI and AUC between chronic kidney
disease patients and controls after maximal stimulation
remained significant (Table 2). There was no significant
difference between patients with cardiorenal failure and
patients with end stage renal failure.
In the chronic kidney disease group almost half of the
patients used aspirin as anti-platelet therapy. Platelet re-
activity in this group does not show a difference between
aspirin users and patients without aspirin. This accounts
for all outcome measurements.
Pre-versus-post dialysis
To rule out an activating effect of the hemodialysis pro-
cedure on baseline platelet activation we studied platelet
activation before and immediate after dialysis. The plate-
let sensitivity (EC50) for TRAP, ADP and CRP did not
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Figure 1 Platelet reactivity. A: The mean fluorescence intensity (MFI) of all platelets, expressed in arbitrary units (AU) and B: area under the
curve (AUC), displayed as median plus interquartile range, for chronic kidney disease patients (CKD) and controls.
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no difference between the maximum reached effect and
AUC on platelet activation when comparing patients
pre- and post dialysis (data not shown).
Discussion
The aim of this study was to investigate the relation be-
tween platelet function and kidney failure in patients
with end stage renal disease and cardiorenal syndrome
using a flow cytometer based, functional platelet assay.
We show that P-selectin expression after stimulationTable 2 Results platelet activation
Controls
N= 19
Maximal MFI TRAP, AU (IQR) 11.4 (9.2-12.2) 9
Maximal MFI ADP, AU (IQR) 2.6 (1.9-3.5)
Maximal MFICRP, AU (IQR) 11.5 (9.5-12.9) 9
EC50 TRAP, μM (IQR) 1.9 (1.5-2.5)
EC50 ADP, μM (IQR) 0.9 (0.6-1.1) 0
EC50 CRP, ng/ml (IQR) 120 (46.7-312.7) 116
AUC TRAP, AU (IQR) 47.1 (41.1-54.2) 39
AUC ADP, AU (IQR) 8.9 (7.9-12.2)
AUC CRP, AU (IQR) 30.3 (22.1-41.9) 23
MFI Mean fluorescence intensity, AU arbitrary units, IQR inter quartile range, EC50 co
AUC Area under the curve.with ADP, CRP and TRAP is lower in patients with
chronic kidney disease as compared to healthy controls.
Furthermore, we demonstrate that the EC50 was not dif-
ferent between groups. This means that platelet sensitiv-
ity itself is not affected for the different agonists, but the
maximal platelet response is significantly lower.
Platelets were activated with 3 different stimuli. We chose
for the agonists TRAP, ADP and CRP, which stimulate the
three major physiological platelet activation pathways.
TRAP activates the thrombin receptor Proteinase Activated
Receptor 1 (PAR-1) on platelets. ADP is normally presentCKD P-value P-value
N=23 Adjusted for age
.7 (7.9-10.8) 0.032 0.095
1.6 (1.2-2.1) 0.002 0.004
.2 (8.5-10.8) 0.004 0.010
2.3 (1.8-2.6) 0.372 0.182
.89 (0.7-1.1) 0.544 0.597
.1 (46.1-270.5) 0.955 0.660
.5 (32.9-44.4) 0.012 0.023
5.8 (3.8-7.3) 0.002 0.003
.4 (18.9-34.7) 0.063 0.322
ncentration of agonist leading to a half maximal P-selectin expression,
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released to activate nearby platelets via the P2Y receptors.
CRP activates the receptor glycoprotein VI, the major
collagen receptor on platelets. So, all 3 stimuli are of
physiological importance.
P-selectin is found in the α-granula of platelets. A defi-
ciency in α-granula could lead to ineffective haemostasis.
Two different explanations are possible for the deficient
platelet α-granula release found in chronic kidney dis-
ease. This could be due to depletion of α-granula itself,
or due to a deficiency in the release of α-granula. An
impaired α-granule release has already been reported in
uraemia [18]. This is further supported by the recent
observations of Schoorl et al. of an increase in platelets
depleted from granules in patients undergoing chronic
haemodialysis [19]. Nevertheless, we cannot exclude an
impairment of release.
The clinical bleeding tendency in uremic patients
received much attention [7]. Haemo- or peritoneal dialysis
was found to improve haemostasis without correcting
platelet aggregation defects. In contrast, compensatory
mechanisms in the form of high von Willebrand factor
(VWF) levels preserved relatively normal adhesion of
uremic platelets to injured vessel wall models [20]. More-
over, as soon as the hematocrit - determining the red blood
cell-mediated radial transport of blood platelets towards
the vessel wall - was corrected by recombinant erythropoi-
etin, clinical bleeding became less prominent. In contrast,
thromboembolic/cardiovascular morbidity remains an im-
portant problem in these patients [21]. Especially in cardi-
orenal failure, there seems no or little benefit from
treatment with antiplatelet agents, whilst risk of bleeding
may increase [22]. Even though reports on platelet reactiv-
ity in patient with chronic kidney disease show conflicting
results [23], it has been attributed to an acquired thrombo-
cytopathy characterized by decreased aggregation of plate-
lets in response to stimuli. There are only a few studies
that used functional tests to study platelet function in
chronic kidney disease. Aggarwal et. al. found a higher
P-selectin expression in patients with end stage renal dis-
ease receiving haemodialysis compared to healthy controls
after stimulation with a single concentration of ADP
(0.2 μM). This suggests an increased reactivity [13]. Moal
et. al performed a similar study in which ADP (200 μM)
and TRAP (50 μM) in a single concentration were used to
stimulate platelets in healthy controls and end stage renal
disease patients receiving haemodialysis. They found a
lower P-selectin expression in patients compared to con-
trols, indicating reduced platelet reactivity in patients with
chronic kidney disease [6]. Most assays used previously are
influenced by in vitro artifacts, platelet isolation and are
dependent on VWF or hematocrit. In our functional assay
there is no role for VWF and hematocrit. Moreover, since
fresh whole blood was used, and samples were fixatedsubsequent to stimulation, in vitro platelet activation was
negligible. We couldn’t find an immediate effect of
haemodialysis, but long term dialysis and classical risk
factors for athero-vascular disease could all be studied with
this assay. Larger populations should be studied in order to
find the factors influencing platelet reactivity in vivo.
In our study, aspirin did not suppress the expression
of P-selectin on platelets. Considering the fact that as-
pirin function is related to inhibition of tromboxane for-
mation and does not influences release of granules, this
is an expected result. Moreover, our finding is in accord-
ance with a study by Stumpf et. al., in which P-selectin
expression on platelets did not show a difference be-
tween patients taking aspirin compared to non-aspirin
users [24]. Further investigation is required to determine
the influence of different drugs on platelet reactivity.
We here demonstrate that the flow cytometry based
platelet activation assay can be used in clinical practice to
study variables influencing platelet response in patients
with renal failure. The assay is based on incubation with
different agonists in whole blood and subsequent fixation.
Platelets are sensitive for in vitro artifacts (especially plate-
let isolation, shear stress, pH and temperature). In our
assay platelets are not isolated. The incubation in whole
blood under standardized condition and the subsequent
fixation step makes in vitro artifacts unlikely. When repeat-
ing the assay within healthy subjects at different blood col-
lection moments, we find high reproducibility. Moreover,
this assay can be used in routine clinical practice.Conclusion
In conclusion, we found that patients with chronic kidney
disease show reduced platelet reactivity in response of
ADP, TRAP and CRP compared to controls. The defect is
probably due to an α-granule defect. Further investigation
is required to determine a correlation between platelet re-
activity and both renal function and the high mortality risk
of patients with chronic kidney disease.
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